X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA JUBILANT LIFE SCIENCES PLETHICO PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x -1.1 29.2 - View Chart
P/BV x 0.0 6.0 0.3% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 PLETHICO PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
JUBILANT LIFE SCIENCES
Mar-14
PLETHICO PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs395187 211.4%   
Low Rs3165 48.1%   
Sales per share (Unadj.) Rs604.4364.3 165.9%  
Earnings per share (Unadj.) Rs32.56.8 474.4%  
Cash flow per share (Unadj.) Rs51.324.5 209.5%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %02.4 0.0%  
Book value per share (Unadj.) Rs473.6164.9 287.2%  
Shares outstanding (eoy) m34.08159.28 21.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.40.3 102.0%   
Avg P/E ratio x6.618.4 35.7%  
P/CF ratio (eoy) x4.25.1 80.8%  
Price / Book Value ratio x0.50.8 58.9%  
Dividend payout %043.8 0.0%   
Avg Mkt Cap Rs m7,26220,061 36.2%   
No. of employees `000NA6.2 0.0%   
Total wages/salary Rs m1,59611,052 14.4%   
Avg. sales/employee Rs ThNM9,383.0-  
Avg. wages/employee Rs ThNM1,786.9-  
Avg. net profit/employee Rs ThNM176.3-  
INCOME DATA
Net Sales Rs m20,59858,034 35.5%  
Other income Rs m386191 202.7%   
Total revenues Rs m20,98458,224 36.0%   
Gross profit Rs m2,8185,786 48.7%  
Depreciation Rs m6422,812 22.8%   
Interest Rs m1,5933,237 49.2%   
Profit before tax Rs m969-72 -1,343.3%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m-138696 -19.9%   
Profit after tax Rs m1,1071,090 101.5%  
Gross profit margin %13.710.0 137.2%  
Effective tax rate %-14.3-965.9 1.5%   
Net profit margin %5.41.9 286.0%  
BALANCE SHEET DATA
Current assets Rs m18,87729,280 64.5%   
Current liabilities Rs m11,89638,912 30.6%   
Net working cap to sales %33.9-16.6 -204.2%  
Current ratio x1.60.8 210.9%  
Inventory Days Days3684 42.6%  
Debtors Days Days19851 390.3%  
Net fixed assets Rs m9,86155,712 17.7%   
Share capital Rs m341155 220.5%   
"Free" reserves Rs m12,33120,968 58.8%   
Net worth Rs m16,13926,265 61.4%   
Long term debt Rs m4,70617,169 27.4%   
Total assets Rs m33,14688,606 37.4%  
Interest coverage x1.61.0 164.5%   
Debt to equity ratio x0.30.7 44.6%  
Sales to assets ratio x0.60.7 94.9%   
Return on assets %8.14.9 166.8%  
Return on equity %6.94.2 165.2%  
Return on capital %12.311.6 106.2%  
Exports to sales %21.437.8 56.6%   
Imports to sales %15.216.5 92.4%   
Exports (fob) Rs m4,40221,933 20.1%   
Imports (cif) Rs m3,1369,567 32.8%   
Fx inflow Rs m4,40222,004 20.0%   
Fx outflow Rs m3,18411,749 27.1%   
Net fx Rs m1,21910,255 11.9%   
CASH FLOW
From Operations Rs m2,4378,026 30.4%  
From Investments Rs m-6,265-1,744 359.2%  
From Financial Activity Rs m2,490-4,447 -56.0%  
Net Cashflow Rs m-1,3371,834 -72.9%  

Share Holding

Indian Promoters % 82.7 45.6 181.4%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 4.3 8.7 49.4%  
FIIs % 5.5 21.2 25.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 21.1 35.5%  
Shareholders   10,665 23,815 44.8%  
Pledged promoter(s) holding % 85.7 15.9 540.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   NOVARTIS  TORRENT PHARMA  DISHMAN PHARMA  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS